Serum KL-6 is a specific biomarker for ILD severity and progression in MDA5+DM patients, since elevated KL-6 levels in the first four weeks of immunosuppressive treatment in MDA5+DM-ILD patients may indicate the occurrence of intractable RPILD. This evidence concerns the gene MUC1 and dermatomyositis.